2023
Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder
Farokhnia M, Rentsch C, Chuong V, McGinn M, Elvig S, Douglass E, Gonzalez L, Sanfilippo J, Marchette R, Tunstall B, Fiellin D, Koob G, Justice A, Leggio L, Vendruscolo L. Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder. Alcohol 2023, 109: 83-84. DOI: 10.1016/j.alcohol.2023.03.071.Peer-Reviewed Original ResearchRacial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
Vickers-Smith R, Justice A, Becker W, Rentsch C, Curtis B, Fernander A, Hartwell E, Ighodaro E, Kember R, Tate J, Kranzler H. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans. American Journal Of Psychiatry 2023, 180: 426-436. PMID: 37132202, PMCID: PMC10238581, DOI: 10.1176/appi.ajp.21111097.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol consumptionAUD diagnosisHispanic veteransWhite veteransUse disordersPrevalence of AUDAlcohol Use Disorders Identification TestUnhealthy alcohol useICD-10 codesAUDIT-C scoresSelf-reported alcohol consumptionAlcohol-related disordersDiagnosis of AUDDisorders Identification TestMaximum scoreSelf-reported raceElectronic health recordsPrimary outcomeAlcohol consumption levelsPotential confoundersHigh prevalenceMillion Veteran ProgramGreater oddsICD-9
2022
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry 2022, 27: 4642-4652. PMID: 36123420, PMCID: PMC10231646, DOI: 10.1038/s41380-022-01736-y.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-ConsumptionEffect of spironolactoneAlcohol consumptionSpironolactone doseNovel pharmacotherapiesUse disordersHuman studiesLarge integrated healthcare systemHeavy episodic alcohol consumptionAlcohol-induced ataxiaMineralocorticoid receptor antagonistsSelf-reported alcohol consumptionBlood alcohol levelsEpisodic alcohol consumptionIntegrated healthcare systemPharmacoepidemiologic cohort studyPotential new pharmacotherapiesCohort studyAlcohol drinkingReceptor antagonistFemale miceFemale ratsNew pharmacotherapiesRat modelChronic pain and substance use disorders among older sexual minority men living with HIV: Implications for HIV disease management across the HIV care continuum
Taylor SW, McKetchnie SM, Batchelder AW, Justice A, Safren SA, O’Cleirigh C. Chronic pain and substance use disorders among older sexual minority men living with HIV: Implications for HIV disease management across the HIV care continuum. AIDS Care 2022, 35: 614-623. PMID: 35653300, PMCID: PMC9715850, DOI: 10.1080/09540121.2022.2076801.Peer-Reviewed Original ResearchConceptsOlder sexual minority menChronic painOpioid use disorderHigher pain ratingsAlcohol use disorderSexual minority menUse disordersPain ratingsMissed appointmentsHIV disease managementHIV care continuumHIV care appointmentsCross-sectional studyMinority menHIV carePain managementMedication adherenceHigher painCare continuumCritical health issuePainHIVSubstance use behaviorsHealth issuesSubstance useDevelopment and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV
Kim HN, Nance RM, Re V, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM. Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 396-404. PMID: 35202048, PMCID: PMC8887786, DOI: 10.1097/qai.0000000000002886.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver diseaseNorth American AIDS Cohort CollaborationStandardized medical record reviewAccessible clinical parametersHIV-specific factorsChronic hepatitis BFibrosis-4 indexMedical record reviewSpontaneous bacterial peritonitisHarrell's C-statisticHepatitis B virusHepatitis C virusAlcohol use disorderRisk prediction modelRace/ethnicityCohort CollaborationESLD riskHepatic impairmentVariceal bleedHepatitis BBacterial peritonitisHepatic encephalopathyRecord reviewClinical parameters
2021
Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV?
Womack JA, Murphy TE, Ramsey C, Bathulapalli H, Leo-Summers L, Smith AC, Bates J, Jarad S, Gill TM, Hsieh E, Rodriguez-Barradas MC, Tien PC, Yin MT, Brandt C, Justice AC. Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 88: 192-196. PMID: 34506360, PMCID: PMC8513792, DOI: 10.1097/qai.0000000000002752.Peer-Reviewed Original ResearchConceptsSubsequent fragility fracturesFragility fracturesAntiretroviral therapySerious fallsRisk factorsVeterans Aging Cohort StudyAging Cohort StudyMultivariable logistic regressionUpper arm fracturesMiddle-aged populationYears of ageAlcohol use disorderCohort studyHip fractureVertebral fracturesArm fracturesInjury codesICD9 codesGeneral populationUse disordersLogistic regressionIntegrase inhibitorsOlder adultsRadiology reportsHIV
2020
Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV
Eyawo O, Deng Y, Dziura J, Justice AC, McGinnis K, Tate JP, Rodriguez‐Barradas M, Hansen NB, Maisto SA, Marconi VC, O’Connor P, Bryant K, Fiellin DA, Edelman EJ. Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV. Alcohol Clinical And Experimental Research 2020, 44: 2053-2063. PMID: 33460225, PMCID: PMC8856627, DOI: 10.1111/acer.14435.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useSignificant alcohol useHeavy drinking daysAlcohol use disorderTimeline FollowbackAlcohol useSelf-reported alcohol useNumber of drinksClinical trialsRisk drinkingUse disordersDrinking daysBiomarker-based evidenceSample of PWHDrinks/dayMean numberSelf-reported alcohol consumptionMagnitude of associationBlood spot samplesLiver diseasePEth levelsTLFB interviewAlcohol consumptionLogistic regressionPatientsImpact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis
McGinnis KA, Skanderson M, Edelman EJ, Gordon AJ, Korthuis PT, Oldfield B, Williams EC, Wyse J, Bryant K, Fiellin DA, Justice AC, Kraemer KL. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug And Alcohol Dependence 2020, 217: 108272. PMID: 32971391, PMCID: PMC7757793, DOI: 10.1016/j.drugalcdep.2020.108272.Peer-Reviewed Original ResearchConceptsAlcohol use disorderDetectable VLVisits/monthUse disordersVeterans Aging Cohort Study (VACS) dataCohort study dataRace/ethnicityUndetectable VLMedian ageTreatment initiationMedication treatmentImproved adherenceHIVBehavioral treatmentFirst monthIntensity groupTreatment intensityMonthsImpact of BehavioralOutcomesLinear regression modelsLongitudinal analysisVisitsVLAdherenceSafety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskDNA methylation signature on phosphatidylethanol, not on self-reported alcohol consumption, predicts hazardous alcohol consumption in two distinct populations
Liang X, Justice AC, So-Armah K, Krystal JH, Sinha R, Xu K. DNA methylation signature on phosphatidylethanol, not on self-reported alcohol consumption, predicts hazardous alcohol consumption in two distinct populations. Molecular Psychiatry 2020, 26: 2238-2253. PMID: 32034291, PMCID: PMC8440221, DOI: 10.1038/s41380-020-0668-x.Peer-Reviewed Original ResearchConceptsHazardous alcohol drinkingSelf-reported alcohol consumptionAlcohol consumptionCohort 2Cohort 1Epigenome-wide association studiesSelf-reported dataHazardous alcohol consumptionAlcohol use disorderDNAm signaturesObjective measuresAlcohol drinkingClinical assessmentUse disordersRobust biomarkersDNA methylation signaturesValidation setDistinct populationsCharacteristic curvePEthEpigenetic biomarkersMethylation signatures
2019
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV
Oldfield BJ, McGinnis KA, Edelman EJ, Williams EC, Gordon AJ, Akgün K, Crystal S, Fiellin LE, Gaither JR, Goulet JL, Korthuis PT, Marshall BDL, Justice AC, Bryant K, Fiellin DA, Kraemer KL. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. Journal Of Substance Use And Addiction Treatment 2019, 109: 14-22. PMID: 31856946, PMCID: PMC6982467, DOI: 10.1016/j.jsat.2019.11.002.Peer-Reviewed Original ResearchConceptsAlcohol use disorderUse disordersHIV statusUninfected individualsVeterans Aging Cohort Study (VACS) dataEvidence-based medicationsNew alcohol use disorderPrevalence of initiationMultivariable logistic regressionPredictors of initiationFacility-level predictorsCohort study dataMedication initiationPrescription fillsMultivariable analysisBlack raceTreatment gapDecreased oddsNew diagnosisPLWHOlder ageLogistic regressionMedicationsHIVSpecific subpopulationsIntegrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The Lancet HIV 2019, 6: e509-e517. PMID: 31109915, PMCID: PMC7161741, DOI: 10.1016/s2352-3018(19)30076-1.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeek 24Use disordersAlcohol treatmentAdverse eventsNumber of drinksTreatment medicationsPhysician managementAlcohol abuseMental Disorders-IV criteriaAlcohol-related careFormal alcohol treatmentKey exclusion criteriaTimeline followback methodMotivational enhancement therapyTreat populationHIV clinicHIV outcomesPrimary outcomeSpecialty referralsMean ageUS National InstitutesWeek 4Medical conditionsExclusion criteriaAssociation Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive days
2016
Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, O'Connor PG, Bedimo R, Gibert C, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Justice AC, Bryant KJ, Fiellin DA. Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients. Contemporary Clinical Trials 2016, 52: 80-90. PMID: 27876616, PMCID: PMC5253227, DOI: 10.1016/j.cct.2016.11.008.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useAlcohol use disorderHIV-positive patientsMotivational enhancement therapyAlcohol useWeek 12Risk drinkingWeek 4Effective evidence-based treatmentsInfectious disease clinicHIV-positive individualsModerate alcohol useEvidence-based treatmentsParticipants meeting criteriaImplementation of interventionsVACS IndexHIV careSecondary outcomesCare trialsDisease clinicHIV morbidityPrimary outcomeAlcohol pharmacotherapyInitial treatmentLiver diseaseHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection
2013
Acetaminophen receipt among HIV‐infected patients with advanced hepatic fibrosis
Edelman EJ, Gordon KS, Re V, Skanderson M, Fiellin DA, Justice AC, Team F. Acetaminophen receipt among HIV‐infected patients with advanced hepatic fibrosis. Pharmacoepidemiology And Drug Safety 2013, 22: 1352-1356. PMID: 24285468, PMCID: PMC4164158, DOI: 10.1002/pds.3517.Peer-Reviewed Original ResearchConceptsAdvanced hepatic fibrosisAcetaminophen exposureHCV statusHepatic fibrosisHIV/HCV-coinfected patientsVeterans Aging Cohort StudyAdvanced liver fibrosisAging Cohort StudyAcetaminophen-induced hepatotoxicitySample of HIVCross-sectional associationsPolytomous logistic regressionAlcohol use disorderCross-sectional analysisAcetaminophen prescriptionsAcetaminophen useHIV-monoinfectedFIB-4Cohort studyLiver injuryPlatelet countLiver fibrosisAlanine aminotransferaseHIVPatients
2011
Treatment outcomes of a stage 1 cognitive–behavioral trial to reduce alcohol use among human immunodeficiency virus‐infected out‐patients in western Kenya
Papas RK, Sidle JE, Gakinya BN, Baliddawa JB, Martino S, Mwaniki MM, Songole R, Omolo OE, Kamanda AM, Ayuku DO, Ojwang C, Owino‐Ong'or W, Harrington M, Bryant KJ, Carroll KM, Justice AC, Hogan JW, Maisto SA. Treatment outcomes of a stage 1 cognitive–behavioral trial to reduce alcohol use among human immunodeficiency virus‐infected out‐patients in western Kenya. Addiction 2011, 106: 2156-2166. PMID: 21631622, PMCID: PMC3208780, DOI: 10.1111/j.1360-0443.2011.03518.x.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAlcohol useDrinking daysLarge human immunodeficiency virusCognitive behavioral therapy interventionAlcohol intervention studyAlcohol use disorderGroup Cognitive Behavioral Therapy InterventionEffect sizeTreatment effect sizeCognitive behavioral therapyDual epidemicsRandomized participantsPatient clinicImmunodeficiency virusPreliminary efficacyHuman immunodeficiencyClinical trialsTreatment outcomesAlcohol abstinenceAssessment-only controlBinge drinkingUse disordersTherapy interventionFeasible intervention